lilly
Lilly and Hanmi enter immunological therapy pact
March 20, 2015Research and Development, Sales and Marketing HM71224, Korea, Sjögren, hanmi, immunological, lilly
Eli Lilly and Korean-based pharma firm Hanmi have entered a collaboration agreement to develop and commercialise an immunological therapy. The …
Big pharma partners with government over $100m dementia fund
March 17, 2015Research and Development, Sales and Marketing Alzheimer's, Biogen IDEC, GSK, J&J, JJ, Pfizer, government, jp morgan, lilly
Lilly, Pfizer, GSK, J&J and Biogen Idec are set to join a $100m Dementia Discovery Fund to boost research into …
German court rules against Lilly in Alimta patent case
March 10, 2015Manufacturing and Production, Sales and Marketing ACS, Actavis, Alimta, NICE, NSCLC, lilly, lung cancer, pemetrexed
A German court has ruled that Lilly’s patent for its lung cancer drug Alimta would not be infringed by generic …
Pharma is boosting pipelines to avoid patent cliff
February 11, 2015Sales and Marketing Biogen IDEC, Moody's, dimethyl fumarate, lilly, pharma, pipelines, sofosbuvir, sovaldi, tecfidera
Pharmaceutical companies have improved their pipelines of new drugs over the last 18 months according to financial analysts Moody’s Investors …
Boehringer and Lilly score FDA yes for Glyxambi
February 3, 2015Sales and Marketing Boehringer, FDA, Glyxambi, Tradjenta, empagliflozin, jardiance, lilly, linagliptin
The FDA has approved Glyxambi (empagliflozin/linagliptin), which has become the first combination of two diabetes drugs in their different classes …
Lilly, BMS and Merck unite for cancer trials
January 13, 2015Research and Development, Sales and Marketing BMS, Cancer, Galunisertib, Merck, NSCLC, keytruda, lilly, oncology, opdivo
Lilly will test some of its compounds in combination with rival cancer drugs from Bristol-Myers Squibb and Merck, the companies …
Lilly appoints head of business development
January 8, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing darren carroll, lilly
Eli Lilly has promoted Darren Carroll to senior vice president of its corporate business development unit. Carroll has fulfilled the …
Lilly’s lung cancer drug sees FDA approval
December 17, 2014Sales and Marketing BMS, Cancer, FDA, NSCLC, cyramza, docetaxel, lilly, opdivo, ramucirumab
Eli Lilly’s lung cancer drug Cyramza (ramucirumab) has been shown the green light by the US Food and Drug Administration …
Pharma to lose $69 billion in five years as patents expire
December 12, 2014Sales and Marketing AstraZeneca, GlobalData, Japanese firm Otsuka, Otsuka, lilly, pharma
Pharma companies are set to lose around $65 billion by 2019 due to drug patent expiries according to research firm …
Analysis finds no Actos bladder cancer link
December 8, 2014Sales and Marketing Actos, Cancer, Takeda, bladder, lilly, pioglitazone, type 2
A large-scale analysis of patient data has found that pioglitazone, the diabetes drug that is the subject of ongoing safety …
AZ and Lilly Alzheimer’s drug enters trials
December 1, 2014Research and Development, Sales and Marketing AZD3293, Alzheimer's, AstraZeneca, LY3314814, lilly
AstraZeneca and Eli Lilly have begun a Phase II/II trial for their Alzheimer’s treatment AZD3293 as the companies hope to …
Takeda and Lilly get Actos trial reprieve
October 29, 2014Sales and Marketing Actos, Takeda, bladder cancer, diabetes, lilly
A judge has dramatically reduced the $9 billion damages bill Takeda and Lilly were set to pay over safety allegations …
Lacklustre sales hit Lilly again
October 24, 2014Sales and Marketing Q3, cymbalta, humilin, lilly, sales, zyprexa
Lilly is enduring one of the bleakest financial years in its history as patent expiries continue to take chunks out …
Hospira recalls drug due to storage hiccup
October 13, 2014Manufacturing and Production, Sales and Marketing FDA, Hospira, Vancocin, Vancomycin hydrochloride, lilly
Hospira has issued a recall of one lot of its injectable vancomycin hydrochloride in the US due to ‘uncontrolled storage …
Novartis says three executives departing firm
October 9, 2014Medical Communications, Sales and Marketing Andrin Oswald, Brian McNamara, GSK, George Gunn, Novartis, lilly, oncology, vaccines
Swiss pharma giant Novartis has announced three of its executives are to leave the firm following deals with Lilly and …
Latest content
FibroFind appoints Lee Borthwick as CEO
